Summary
This prediction ended on 05.12.17 with a price of €12.10. The prediction for Evotec SE disappointed with a performance of -10.70%. phonebroker has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Evotec SE | 0.518% | 0.518% | -41.789% | -72.004% |
| iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
| iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
| iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
| iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
According to phonebroker what are the pros and cons of Evotec SE for the foreseeable future?
Pros
Medium risks for its business
Cons
Comments by phonebroker for this prediction
In the thread Evotec AG diskutieren
phonebroker stimmt dem Sentiment von 'Buy' zu
(Vom Mitglied beendet)